Genzyme is currently trading at a premium to the $69 per share cash offer:
http://10xreturn.com/stock_center/merger...
However it sounds as if "Sanofi will eventually have to raise its offer, already rejected by Genzyme a month ago" and that a price somewhere in the range of $75 per share is more likely.
Thus at a price of $71 per share right now is Genzyme a buy or sell?
Could a derivative such as a future or an option be a safer buy than common stock?
http://10xreturn.com/stock_center/merger...
However it sounds as if "Sanofi will eventually have to raise its offer, already rejected by Genzyme a month ago" and that a price somewhere in the range of $75 per share is more likely.
Thus at a price of $71 per share right now is Genzyme a buy or sell?
Could a derivative such as a future or an option be a safer buy than common stock?